A Randomized, Double-Blind, Placebo-Controlled Phase II/III Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HMPL-523 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Sovleplenib (Primary)
- Indications Autoimmune haemolytic anaemia
- Focus Proof of concept; Registrational; Therapeutic Use
- Acronyms ESLIM-02
- Sponsors Hutchison MediPharma
- 16 Jul 2024 Status changed from active, no longer recruiting to recruiting.
- 24 Jun 2024 According to a HUTCHMED media release, company will host R&D update in Shanghai, China, and via webcast on Tuesday, July 9, 2024 to provide updates on certain programs within HUTCHMED's extensive and innovative pipeline. This will include updates on the Phase III ESLIM-01 and Phase II/III ESLIM-02 studies he surufatinib Phase II/III study for metastatic pancreatic ductal adenocarcinoma, and the Phase III RAPHAEL study of our IDH1/2 inhibitor HMPL-306 in acute myeloid leukemia.
- 17 May 2024 According to a HUTCHMED media release, data from the study will be presented at the upcoming European Hematology Association (EHA) Hybrid Congress, taking place on June 13-16, 2024 in Madrid, Spain and online.